New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 25, 2014
16:17 EDTAMGN, WDCWestern Digital CFO Leyden to retire, Olivier Leonetti to succeed
Western Digital (WDC) announced that CFO Tim Leyden is retiring. He is being succeeded by Olivier Leonetti, who has served as vice president, finance at Amgen (AMGN) from 2011. Leyden will remain with the company through January 2015 in a transition role and advisory capacity to president and chief executive officer Steve Milligan and to Leonetti for an interim period to ensure a smooth transition. The changes are effective as of September 8.
News For WDC;AMGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 29, 2015
16:16 EDTWDCWestern Digital reports Q4 EPS $1.51, consensus $1.45
Subscribe for More Information
15:59 EDTWDCNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 47c... MetLife (MET), consensus $1.48... Williams (WMB), consensus 24c... Vertex (VRTX), consensus (58c)... O'Reilly Automotive (ORLY), consensus $2.26... NXP Semiconductors (NXPI), consensus $1.37... Marriott (MAR), consensus 81c... Fiserv (FISV), consensus 94c... Western Digital (WDC), consensus $1.45... SBA Communications (SBAC), consensus 9c... Whole Foods (WFM), consensus 45c... Lincoln National (LNC), consensus $1.53... Lam Research (LRCX), consensus $1.47... ServiceNow (NOW), consensus (2c)... Qorvo (QRVO), consensus $1.06... Hologic (HOLX), consensus 39c.
15:08 EDTWDCNotable companies reporting after market close
Subscribe for More Information
14:12 EDTWDCEarnings Watch: Hard drive makers report amid PC sector fears
Western Digital (WDC) and Seagate (STX) are expected to report quarterly results on July 29 and 31 with conference calls scheduled for 5:00 pm ET and 9:00 am ET, respectively. The two companies develop and manufacture computer storage solutions, including hard disk drives. EXPECTATIONS: Analysts are expecting Western Digital to report earnings per share of $1.45 on revenue of $3.25B, while Seagate is expected to report earnings per share of 64c on revenue of $2.92B. During its last earnings conference call, Western noted a "cautious" near-term outlook and forecast Q4 EPS to be $1.50-$1.60 on revenue of $3.3B-$3.4B. PRELIMINARY RESULTS: On July 13, Seagate reported preliminary Q4 revenue of $2.9B, adjusted gross margins of 27%, and 45M unit shipments, driven by what the company characterized as "lower than expected intra-quarter demand." The company had previously guided Q4 revenue to $3.2B-$3.3B, and analysts were looking for $3.19B in revenue at the time. LAST QUARTER: On April 17, Seagate reported Q3 adjusted EPS of $1.08 against expectations for $1.04, and revenue of $3.3B versus estimates of $3.4B. Following that, Western Digital reported Q3 EPS of $1.87 on April 28 versus estimates of $1.89, and revenue of $3.5B against expectations for $3.6B. NEWS: On May 1, Seagate announced plans to combine its Cloud Systems and Electronic Solutions groups, and on July 14, the company said it extended its alliance with HP (HPQ). STREET RESEARCH: On May 15, RBC called Western Digital shares "compelling" due to multiple near-term positive catalysts, though Morgan Stanley said on May 19 that it was just "cautiously optimistic" on Western because of softened growth expectations for the general PC market. On May 28, Goldman Sachs called fears of PC weakness overdone and upgraded Western Digital to Buy, saying the company's increasingly enterprise-heavy mix gives it a healthy long-term profit forecast. On June 12, Longbow reported that its hard drive price checks were not quite as bad as it had feared, adding that Western Digital's guidance appears achievable while Seagate's forecast appeared at risk. Heading closer to earnings, Citi said on July 2 that it expects somewhat weak quarterly results for the two hard drive giants but recommended buying both Western Digital and Seagate shares on any perceived post-earnings weakness. Stifel somewhat echoed that point on July 8, saying investor sentiment seemed overly negative towards Western, with traders potentially underestimating the company's shift towards enterprise products. Note that on July 23, Morgan Stanley said its June CIO survey indicated incremental enterprise IT budget weakness, leading the research firm to downgrade Western Digital to Equal Weight and drop Seagate two notches to Underweight. On the M&A front, Susquehanna said on May 29 that SanDisk (SNDK) remained an attractive takeover target, with Western Digital looking like a likely buyer. However, RBC and CLSA both raised doubts on June 5 about the possibility of such a deal. PRICE ACTION: Shares of Western Digital are up 1.34% to $78.83 ahead of Wednesday's report, while Seagate is up 0.84% to $49.28.
07:49 EDTAMGNAmgen July weekly volatility elevated into Q2 and outlook
Amgen July weekly call option implied volatility is at 61, August is at 32, September is at 29; compared to its 52-week range of 18 to 34, suggesting large near term price movement into the expected release of Q2 results on July 30.
05:59 EDTAMGNStocks with implied volatility movement; AMGN CLF
Stocks with implied volatility movement; Amgen (AMGN) 30, Cliffs Natural (CLF) 125 according to iVolatility.
July 28, 2015
07:34 EDTAMGNJefferies sees entry point for Aegerion, upgrades to Buy
Subscribe for More Information
July 24, 2015
15:00 EDTAMGNBroader label for PCSK9 drug positive for Regeneron, Amgen, says Deutsche Bank
Subscribe for More Information
12:44 EDTAMGNAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTAMGNFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
July 23, 2015
10:00 EDTWDCOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:10 EDTAMGNAmgen submits NDA for Kyprolis in relapsed multiple myeloma
Amgen submitted a supplemental New Drug Application to the FDA for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Kyprolis currently has accelerated approval in the U.S. for the treatment of patients with relapsed multiple myeloma as a monotherapy. The sNDA is based on data from the global Phase 3 ENDEAVOR trial in which relapsed multiple myeloma patients treated with Kyprolis and dexamethasone lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade.
06:29 EDTWDCWestern Digital downgraded to Equal Weight from Overweight at Morgan Stanley
Subscribe for More Information
July 21, 2015
12:47 EDTAMGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:49 EDTAMGNNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
07:12 EDTAMGNAmgen's Repatha granted marketing authorization by EC
Amgen announced that the European Commission, or EC, has granted marketing authorization for Repatha, or evolocumab, the first proprotein convertase subtilisin/kexin type 9, or PCSK9, inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
July 16, 2015
16:05 EDTAMGNAmgen announces Phase 2 trial results evaluating Blincyto
Subscribe for More Information
July 15, 2015
10:01 EDTWDCOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: AGCO (AGCO) upgraded to Market Perform from Underperform at Wells Fargo... Anglo American (AAUKY) upgraded to Outperform from Neutral at Credit Suisse... Avis Budget (CAR) upgraded to Buy from Hold at Deutsche Bank... Brookfield Renewable (BEP) upgraded to Neutral from Underperform at Credit Suisse... CSX (CSX) upgraded to Outperform from Sector Perform at RBC Capital... Centene (CNC) upgraded to Buy from Hold at Jefferies... Commerce Bancshares (CBSH) upgraded to Market Perform at Raymond James... Entegris (ENTG) upgraded to Buy at Craig-Hallum... Guess (GES) upgraded to Market Perform from Underperform at Telsey Advisory... Hertz (HTZ) upgraded to Buy from Hold at Deutsche Bank... Iberdrola (IBDRY) upgraded to Buy from Hold at Societe Generale... Liberty Global (LBTYA) upgraded to Conviction Buy from Buy at Goldman... LinkedIn (LNKD) upgraded to Overweight from Equal Weight at Barclays... Lonmin (LNMIY) upgraded to Neutral from Sell at Goldman... Navient (NAVI) upgraded to Overweight from Equal Weight at Barclays... NetApp (NTAP) upgraded to Sector Weight from Underweight at Pacific Crest... Omnicom (OMC) upgraded to Outperform from Market Perform at Wells Fargo... PTC Therapeutics (PTCT) upgraded to Overweight from Neutral at JPMorgan... Panera Bread (PNRA) upgraded to Overweight from Underweight at Piper Jaffray... Primerica (PRI) upgraded to Strong Buy from Market Perform at Raymond James... Sands China (SCHYY) upgraded to Overweight from Equal Weight at Barclays... Seagate (STX) upgraded to Buy at Craig-Hallum... Western Digital (WDC) upgraded to Buy from Hold at Craig-Hallum... Wolseley (WOSYY) upgraded to Overweight from Neutral at JPMorgan.
08:59 EDTWDCWestern Digital upgraded to Buy at Craig-Hallum
As previously reported, Craig-Hallum upgraded Western Digital to Buy from Hold and maintained its $89 price target. The firm believes PC data points will improve in 2H and management remains committed to remain committed to returning cash flow to investors.
07:36 EDTWDCWestern Digital upgraded to Buy from Hold at Craig-Hallum
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use